[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ars Pharmaceuticals Inc (SPRY)

Ars Pharmaceuticals Inc (SPRY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 724,897
  • Shares Outstanding, K 99,301
  • Annual Sales, $ 84,280 K
  • Annual Income, $ -171,300 K
  • EBIT $ -142 M
  • EBITDA $ -184 M
  • 60-Month Beta 0.93
  • Price/Sales 8.75
  • Price/Cash Flow N/A
  • Price/Book 6.42

Options Overview Details

View History
  • Implied Volatility 83.56% (-3.18%)
  • Historical Volatility 49.80%
  • IV Percentile 33%
  • IV Rank 11.67%
  • IV High 341.30% on 03/30/26
  • IV Low 49.51% on 07/11/25
  • Expected Move (DTE 30) 1.28 (16.98%)
  • Put/Call Vol Ratio 0.16
  • Today's Volume 85
  • Volume Avg (30-Day) 840
  • Put/Call OI Ratio 0.19
  • Today's Open Interest 6,216
  • Open Int (30-Day) 10,839
  • Expected Range 6.24 to 8.79

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.44
  • Number of Estimates 4
  • High Estimate $-0.38
  • Low Estimate $-0.57
  • Prior Year $-0.46
  • Growth Rate Est. (year over year) +4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.03 +6.54%
on 05/15/26
9.57 -21.73%
on 05/06/26
-0.69 (-8.44%)
since 04/17/26
3-Month
7.03 +6.54%
on 05/15/26
9.65 -22.39%
on 03/10/26
-1.95 (-20.66%)
since 02/19/26
52-Week
6.66 +12.46%
on 11/21/25
18.90 -60.37%
on 06/27/25
-6.77 (-47.48%)
since 05/19/25

Most Recent Stories

More News
Canadian CPI Featured in Short Week

Monday U.S. Featured Earnings Baidu Inc (NASDAQ:BIDU) (Q1) EPS of $1.50, compared to ...

NVDA : 220.73 (-0.72%)
DE : 559.35 (-0.91%)
BEKE : 18.89 (+6.12%)
SPRY : 7.51 (+2.88%)
TJX : 152.16 (+1.27%)
ADI : 416.11 (-0.59%)
BIDU : 138.25 (+0.39%)
TCOM : 49.47 (+0.30%)
MUFG : 19.49 (+1.56%)
KEYS : 331.85 (-2.53%)
HTHT : 45.56 (+0.11%)
HD : 302.36 (+0.85%)
ARS Pharmaceuticals Q1 Earnings Call Highlights

ARS Pharmaceuticals (NASDAQ:SPRY) reported first-quarter 2026 revenue of $22.7 million as executives said the company is working to expand access, reduce prescribing friction and build momentum for neffy,...

SPRY : 7.51 (+2.88%)
ARS Pharmaceuticals Reports First Quarter 2026 Financial Results and Corporate Update

Q1 2026 total revenue of $22.7 million including  neffy ® (epinephrine nasal spray) U.S. net product revenue of $17.5 million CVS Caremark proposal in final stages of approval process;...

SPRY : 7.51 (+2.88%)
ARS Pharmaceuticals Revenue Accelerates but the Burn Rate Keeps Getting Worse

Barchart Research What to Expect from SPRY Earnings SPRY Generated May 14, 2026 Current Price $7.94 EPS Estimate $$-0.53 Consensus Rating Strong Buy Average Move 8.26% ARS Pharmaceuticals Revenue Accelerates...

SPRY : 7.51 (+2.88%)
ARS Pharmaceuticals Strengthens Leadership Team with Appointment of Industry Veteran Donn Casale as President

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering patients and their caregivers to better protect against severe...

SPRY : 7.51 (+2.88%)
ARS Pharmaceuticals Announces Conference Call and Webcast for its First Quarter 2026 Financial Results

SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients...

SPRY : 7.51 (+2.88%)
neffy® (epinephrine nasal spray) Approved in Canada as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis)

neffy offers a new delivery method for epinephrine in Canada for adults and children ( > 30 kg) living with severe allergic reactions ALK- Abelló A/S, which licenses the rights to market ...

SPRY : 7.51 (+2.88%)
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label

Children were previously required to weigh ≥33 lbs. and

SPRY : 7.51 (+2.88%)
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization

neffy delivers $72.2 million of U.S. net product revenue in first full year Intranasal epinephrine platform advances with Phase 2b CSU data expected mid-2026 Strong balance sheet of $245.0...

SPRY : 7.51 (+2.88%)
ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences

SAN DIEGO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients...

SPRY : 7.51 (+2.88%)

Business Summary

ARS Pharmaceuticals Inc. is dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions which could lead to anaphylaxis. The company is developing neffy(TM) an intranasal epinephrine product in clinical development for patients and their caregivers...

See More

Key Turning Points

3rd Resistance Point 7.91
2nd Resistance Point 7.70
1st Resistance Point 7.50
Last Price 7.51
1st Support Level 7.09
2nd Support Level 6.88
3rd Support Level 6.68

See More

52-Week High 18.90
Fibonacci 61.8% 14.22
Fibonacci 50% 12.78
Fibonacci 38.2% 11.34
Last Price 7.51
52-Week Low 6.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.